🎉 M&A multiples are live!
Check it out!

DBV Technologies Valuation Multiples

Discover revenue and EBITDA valuation multiples for DBV Technologies and similar public comparables like Schott Pharma, Nanoform, and Peptron.

DBV Technologies Overview

About DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.


Founded

2002

HQ

France
Employees

104

Financials

LTM Revenue $3.5M

LTM EBITDA -$156M

EV

$158M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

DBV Technologies Financials

DBV Technologies has a last 12-month revenue of $3.5M and a last 12-month EBITDA of -$156M.

In the most recent fiscal year, DBV Technologies achieved revenue of n/a and an EBITDA of -$72.4M.

DBV Technologies expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See DBV Technologies valuation multiples based on analyst estimates

DBV Technologies P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$89.7M -$72.4M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$105M -$103M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

DBV Technologies Stock Performance

As of April 15, 2025, DBV Technologies's stock price is EUR 1 (or $1).

DBV Technologies has current market cap of EUR 181M (or $194M), and EV of EUR 147M (or $158M).

See DBV Technologies trading valuation data

DBV Technologies Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$158M $194M XXX XXX XXX XXX $-0.40

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

DBV Technologies Valuation Multiples

As of April 15, 2025, DBV Technologies has market cap of $194M and EV of $158M.

DBV Technologies's trades at 44.5x LTM EV/Revenue multiple, and -1.0x LTM EBITDA.

Analysts estimate DBV Technologies's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for DBV Technologies and 10K+ public comps

DBV Technologies Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $158M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -2.2x XXX XXX XXX
P/E -2.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get DBV Technologies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

DBV Technologies Valuation Multiples

DBV Technologies's NTM/LTM revenue growth is 544%

DBV Technologies's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.8M for the same period.

Over next 12 months, DBV Technologies's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate DBV Technologies's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for DBV Technologies and other 10K+ public comps

DBV Technologies Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -19% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

DBV Technologies Public Comps

See public comps and valuation multiples for Drug Delivery Systems and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
LTR Pharma XXX XXX XXX XXX XXX XXX
Starpharma XXX XXX XXX XXX XXX XXX
Schott Pharma XXX XXX XXX XXX XXX XXX
Nanoform XXX XXX XXX XXX XXX XXX
Peptron XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

DBV Technologies M&A and Investment Activity

DBV Technologies acquired  XXX companies to date.

Last acquisition by DBV Technologies was  XXXXXXXX, XXXXX XXXXX XXXXXX . DBV Technologies acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by DBV Technologies

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About DBV Technologies

When was DBV Technologies founded? DBV Technologies was founded in 2002.
Where is DBV Technologies headquartered? DBV Technologies is headquartered in France.
How many employees does DBV Technologies have? As of today, DBV Technologies has 104 employees.
Who is the CEO of DBV Technologies? DBV Technologies's CEO is Mr. Daniel Tasse.
Is DBV Technologies publicy listed? Yes, DBV Technologies is a public company listed on PAR.
What is the stock symbol of DBV Technologies? DBV Technologies trades under DBV ticker.
When did DBV Technologies go public? DBV Technologies went public in 2012.
Who are competitors of DBV Technologies? Similar companies to DBV Technologies include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform.
What is the current market cap of DBV Technologies? DBV Technologies's current market cap is $194M
What is the current revenue of DBV Technologies? DBV Technologies's last 12-month revenue is $3.5M.
What is the current EBITDA of DBV Technologies? DBV Technologies's last 12-month EBITDA is -$156M.
What is the current EV/Revenue multiple of DBV Technologies? Current revenue multiple of DBV Technologies is 44.5x.
What is the current EV/EBITDA multiple of DBV Technologies? Current EBITDA multiple of DBV Technologies is -1.0x.
Is DBV Technologies profitable? Yes, DBV Technologies is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.